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responsibility of XAbstract To enable reliable quantiﬁcation of natamycin in rabbit and human plasma, a validated,
sensitive and selective liquid chromatography–tandem mass spectrometry assay was developed.
The chromatographic separation was achieved isocratically on a Cyano column using methanol:
aqueous 3.5 mM ammonium acetate (pH 4) (90:10 v/v). The assay was validated over a
concentration range of 6.25–400 ng/mL with lower limit of detection of 3.12 ng/mL. Quantiﬁcation
was performed using the transitions 664.5-137.2m/z for natamycin and 923.5-183.4m/z for the
IS. The method was validated with respect to linearity, accuracy, precision, recovery and stability.
This assay has been successfully applied to a pharmacokinetic study of natamycin in NZ rabbit and
plasma protein binding in human plasma.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Natamycin (NAT), known as pimaricin, is a naturally occur-
ring product of Streptomyces species. NAT has been used toersity. Production and hosting by E
.003
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(R.S. Bhatta).
i’an Jiaotong University.treat several human clinical fungal infections, such as candi-
diasis and trichomoniasis [1–3]. NAT medical utilization is
currently conﬁned to the topical treatment (commercially
available as topical 5% suspension for ophthalmic use) of
corneal fungal infections and prevention of such infections in
contact lens users [2,4]. As reported in British National
Formulary, natamycin is sold under the trade name ‘‘Pimafu-
cin’’ in oral suspension, suspension for inhalation, cream and
vaginal tablet formulations. The parenteral formulation of
NAT offers a best alternative as it could be used for systemic
fungal infections [5]. NAT has been approved as food
preservative in several countries and applied widely in cheese,
meat products, wine and other foods [6,7]. Besides this, NATlsevier B.V. All rights reserved.
Fig. 1 MS/MS ion spectra of natamycin.
LC–MS/MS assay of natamycin 145is also used as feed efﬁciency agent in feed of swine, poultry,
dairy animals, rabbits, ﬁsh and other animals [8]. Based on its
potential to be used in many ways such as food preparations
and in various fungal infections (topically and systemic), it will
be interesting to explore its pharmacokinetics characteristics.
The in-vivo preclinical and clinical disposition characteristics
of NAT have not been reported in details, probably due to
lack of sensitive bioanalytical method.
Presently, there are few articles reported for the analytical
method of NAT in wine and other food stuff [7,9,10].
However, only two bioanalytical methods have been
reported. One describes the HPLC-UV bioanalytical method
for estimation of NAT in canine plasma and the other LC–
MS/MS method for ocular pharmacokinetics [5,11]. The
application of LC–MS/MS is currently considered the
method of choice for supporting pharmacokinetic and
toxicokinetic studies due to its selectivity, sensitivity and
short run time [12,13].
Therefore, the objective of this study was, in ﬁrst instance
the development of a rapid, selective, highly sensitive and
robust method for the determination of NAT in human and
rabbit plasma. The validated method has been successfully
applied to the evaluation of NAT pharmacokinetics in NZ
rabbits after i.v. administration and its plasma protein binding
determination in human plasma. The present method can also
be exploited in preclinical and clinical pharmacokinetic/tox-
icological evaluation of NAT.2. Materials and methods
2.1. Chemicals and materials
Natamycin and amphotercin B (Internal standard; IS) of phar-
maceutical grade were gifted by Cipla Ltd. (Mumbai, India).
Methanol (HPLC grade) was purchased from Sisco Research
Laboratories Pvt. Ltd. (Mumbai, India). Oasis HLB 3 cc, 60 mg
solid phase extraction cartridges were procured from Waters
(India) Pvt. Ltd. Ultrapure water was obtained from a Milli-Q
PLUS PF water puriﬁcation system. All other reagents were of
analytical grade.2.2. LC–MS/MS conditions
The system consisted of a Shimadzu UFLC pump (LC-20AD)
with degasser (DGU-20A3) and autosampler (SIL-HTc), with an
API-4000Q trap mass spectrometer (Applied Biosystems-SCIEX,
Canada), in negative ionization mode. In this study, chromato-
graphic separation was achieved on a Phenomenex, Luna 3 mm
Cyano column (3 mm, 100 mm 2 mm). The mobile phase was
composed of ammonium acetate buffer (3.5 mM, pH 4):methanol
(10:90, v/v), and eluted at a ﬂow rate of 0.3 mL/min. Injection
volume was set at 20 mL. The spray needle voltage was 4500 V
and the source temperature was 300 1C. The curtain gas was 10 psi
and entrance potential was 10 V. The collision energy was
35 eV for both NAT and IS. The detection and quantiﬁcation of
analytes were performed using the multiple reaction monitoring
(MRM) mode using ion precursor-product ion combinations of
664.5-137.2m/z for NAT (Fig. 1) and 923.5-183.4m/z for the
IS. Data acquisition and processing were performed with Analyst
software 1.4.1.2.3. Preparation of standard and quality control samples
The standard stock solutions of 1 mg/mL for NAT and
amphotericin B (IS) were prepared in methanol and DMSO
respectively. Further working standards of NAT and IS were
prepared in methanol. Calibration standard and quality control
(QC) samples were prepared by adding appropriate volumes
of working standard solutions to 200 mL blank human plasma.
The ﬁnal calibration standard concentrations were in the range
of 6.25–400 ng/mL. Final QC samples concentrations were 7.5,
12.5, 125 and 375 ng/mL. In all calibration and QC samples
20 mL IS (20 mg/mL) was added.
2.4. Sample preparation
The calibration standards, QC and plasma samples were
extracted by solid phase extraction (SPE) using Oasis HLB
cartridge. Prior to SPE, a 20 mL aliquot of IS working solution
was added to all plasma samples except blank plasma sample,
to which a 750 mL aliquot of 0.1% ammonia solution was
added. The SPE cartridge was conditioned sequentially with
2.0 mL of methanol and 1.0 mL of ultrapure water (UPW).
Then plasma sample mixture and 250 mL of 0.1% aqueous
ammonia solution were loaded. The cartridge was sequentially
washed with 1.0 mL UPW and 1 mL of 5% aqueous methanol.
Finally NAT was eluted from cartridge with 2.0 mL methanol.
The eluted samples were dried under vacuum and residue was
reconstituted in 200 mL of methanol and 20 mL was injected into
LC–MS/MS.
2.5. Method validation
The method was validated for selectivity, accuracy, precision,
recovery, matrix effect and stability according to the FDA
guideline for validation of bioanalytical methods [14]. The
lower limit of detection (LLOD) was evaluated by spiking the
analyte into six replicates in pooled rabbit and human plasma
followed by extraction and quantiﬁcation. The speciﬁcity was
investigated for potential matrix interferences in six lots of
blank rabbit and human plasma by extraction and inspection
of the resulting chromatograms for interfering peaks at the
retention times of the analyte and IS. Linearity was tested at
six different concentrations, covering a range of 6.25–400 ng/
mL. The calibration curves were established by plotting the
peak area ratio of analyte and IS versus concentration. To
evaluate the precision and accuracy of the method, QC
samples at four concentration levels (7.5, 12.5, 125 and
375 ng/mL of NAT) were analyzed in ﬁve replicates on ﬁve
different days. The recovery of NAT and the IS from human
plasma during extraction was determined at 12.5 and 400 ng/mL
Fig. 2 Typical MRM chromatograms of (A) overlay of blank plasma and NAT spiked in human plasma (25 ng/mL), (B) overlay
of blank plasma and IS spiked in plasma for IS (2 mg/mL).
Fig. 3 MRM chromatograms of (A) overlay of blank plasma and NAT spiked (25 ng/mL) in rabbit plasma, (B) overlay of blank plasma
and IS spiked in plasma for IS (2 mg/mL), (C) pharmacokinetic sample at 30 min of NAT and (D) pharmacokinetic sample at 30 min of
IS.
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samples spiked with the analyte prior to extraction with those
spiked post-extraction. The matrix effect was assessed at
concentrations of 12.5 and 400 ng/mL for NAT and IS by
comparing the corresponding peak areas of the post-extraction
spiked samples to those of the standard solutions evaporated
directly and reconstituted in mobile phase [15]. All stability
studies were carried out at 12.5 and 400 ng/mL.
2.6. Application of the method
2.6.1. In-vitro plasma protein binding
NAT plasma protein binding in human plasma was performed at
three different concentrations (6.25, 50 and 400 ng/mL). Thebound and unbound fractions of NAT were separated from
human plasma samples by ultra-ﬁltration through the centrifuge
micro partition system (Amicon, Centrifree device Inc., MA,
USA) [16,17]. Samples in duplicates (0.5 mL) were placed in
Centrifree devices and centrifuged at 1500g for 10 min to collect
approximate 10% (100 mL) of the original volume of plasma as
ultraﬁltrate. Non-speciﬁc binding of NAT was determined by
spiking test concentration into 0.01 M phosphate buffer (pH 7.4)
and applied same procedure as plasma. The in-vitro samples and
their respective ultra-ﬁltrates were analyzed by LC–MS/MS. The
non-speciﬁc binding and plasma protein binding were determined
using the following equations:Non-speciﬁc binding (%)
¼100[(conc. in buffer ultraﬁltrate)
Table 2 Stability data of NAT in NZ rabbit and human plasma.
Storage conditions Nominal
conc.
(ng/mL)
Rabbit plasma Human plasma
Measured
mean
conc. (ng/mL)
CV
(%)
Accuracy
(%)
Measured
mean conc.
(ng/mL)
CV
(%)
Accuracy
(%)
Freeze–thaw stability (80 1C) 12.5 13.270.7 5.5 98.9 13.170.8 6.1 101.7
400 429.6714.2 3.3 99.4 422.4719.3 4.6 95.2
Long-term stability (80 1C, 30 days) 12.5 12.970.1 3.6 101.2 12.870.4 1.6 103.7
400 408.373.6 3.1 102.5 402.6711.6 2.9 96.4
Auto-sampler stability (4 1C, 24 h) 12.5 12.470.9 6.8 94.2 12.270.5 4.2 91.5
400 406.7 77.3 4.8 97.1 407.0715.1 3.9 99
Dry residue stability (4 1C, 48 h) 12.5 12.270.4 2.9 93.1 12.170.6 5.0 91.2
400 411.375.0 1.2 98.2 417.3712.8 3.1 101.5
Bench-top stability (at ambient temperature,
6h)
12.5 13.470.8 6.2 101.8 12.470.5 4.0 93.5
400 434.1712.7 6.0 103.7 444.0711.3 2.6 108.0
Table 1 Accuracy (% bias) and precision (% RSD) of NAT.
Conc. Theoretical conc. (ng/mL) Rabbit plasma Human plasma
Intra-assay Inter-assay Intra-assay Inter-assay
% Bias RSD (%) % Bias RSD (%) % Bias RSD (%) % Bias RSD (%)
LLOQ 6.5 1.4 5.1 4.8 7.9 0.2 3.5 1.2 4.2
LQC 7.5 8.9 8.9 9.8 11.8 5.4 5.4 4.3 3.1
MQC 125.0 0.8 4.9 2.8 5.8 0.8 4.1 1.4 7.2
HQC 375.0 1.1 4.6 2.2 6.3 2.7 3.9 3.1 8.0
LC–MS/MS assay of natamycin 147 100/conc. in buffer]
Plasma protein binding (%)
¼100[(conc. in plasma ultraﬁltrate)
 100/conc. in plasma].2.6.2. Pharmacokinetic study
The animal studies were carried out as per the guidelines of the
local ethical committee on animal experimentation. To assess
the applicability of the assay, intravenous pharmacokinetic at
1 mg/kg dose was carried out in NZ rabbit (n¼3). NAT was
administered i.v. at a dose of 1.0 mg/kg. Blood samples
(1.0 mL) were collected into heparinized tubes via the
marginal ear vein at 0.083, 0.16, 0.33, 0.5, 0.75, 1, 2, 3, 4, 6,
and 8 h post-dose. Plasma was separated by centrifugation
(2200 rpm, 5 min) and stored at 80 1C until analysis. The
plasma concentration versus time data for NAT was analyzed
with a non-compartmental method using the WinNonlin
software (ver. 5.1; Pharsight, Mountain View, CA, USA).3. Results and discussion
3.1. Method development and validation
Our previously developed LC–MS/MS assay was reported for
estimation of NAT in tear for ocular pharmacokinetic studies [11].
In view of need for the sensitive and selective LC–MS/MS methodfor estimation of NAT in plasma (human and rabbit) was
developed. No signiﬁcant interference was detected at the retention
times of the analyte and IS, in the six different blank plasma
chromatograms (Figs. 2 and 3). Calibration curves were linear
over the range 6.25–400.0 ng/mL for NAT. Correlation coefﬁ-
cients (r2) were 40.9981 for NAT with a weighted factor 1/x2.
The limit of detection (LOD) was 3.12 ng/mL. The obtained data
for intra-run and inter-run precision and accuracy were within the
acceptable limit as per FDA guideline (Table 1). The mean
recovery of NAT (n¼5), determined at 12.5 and 400 ng/mL,
was 72.37% and 84.10%, respectively. NAT was stable during
three freeze–thaw cycles, long-term (30 days) and auto-sampler
stability (24 h) at 4 1C (Table 2). The matrix effect for NAT at
12.5, and 400 ng/mL concentration levels in plasma was less than
715 %. Thus no signiﬁcant matrix effect was observed.3.2. Application of the method
3.2.1. In-vitro plasma protein binding studies
The present in-vitro study was carried out to determine the extent
of plasma protein binding of NAT. Bound and unbound drug
from spiked/treated plasma was separated by the ultra-ﬁltration
technique. Plasma protein binding of NAT was found 76.23%,
73.40% and 71.37% at 6.25, 50 and 400 ng/mL respectively.
Concentration dependent human plasma protein binding was not
observed within the selected concentration range (6.25–400 ng/
mL). Non-speciﬁc binding of NAT was foundo5%.
Fig. 4 Plasma concentration–time proﬁle of NAT after intrave-
nous administration (n¼3).
Table 3 Pharmacokinetic proﬁle of NAT after intrave-
nous administration in NZ rabbit.
Parameters Estimates
C0 (ng/mL) 5377322
AUC0N (hnng/mL) 162755
t1/2 (h) 1.470.4
Vd (L/kg) 8.372.8
Cl (L/h/kg) 6.671.9
Abbreviation: C0: concentration at time zero, AUC: area under
the curve from 0 to N, Vd: volume of distribution,
Cl: clearance, t1/2: terminal half-life, n¼3.
Y.S. Chhonker et al.1483.2.2. Pharmacokinetics study
The validated method performed well during sample analysis
of preclinical pharmacokinetics samples. The concentration–
time curve was smooth enough to estimate pharmacokinetic
parameters and the elimination phase was well ﬁtted to the
ﬁrst-order one compartment pharmacokinetic model (Fig. 4
and Table 3). The sensitivity and speciﬁcity of the assay were
sufﬁcient for accurately characterizing the pharmacokinetics
proﬁle of NAT in NZ rabbits.4. Conclusion
The current validated LC–MS/MS method for NAT offers
signiﬁcant advantages in terms of sensitivity and selectivity,
sample preparation, short run time (5 min) and lower volume
of sample requirements (200 mL). From the results of all the
validation parameters and applicability of the assay, we can
conclude that the present method can be satisfactorily used for
pharmacokinetic characterization (both preclinical and clin-
ical) of NAT. The present method can also be exploited in
pharmacokinetic/toxicokinetic evaluation of NAT with
desired precision and accuracy along with high-throughput.
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